Join
Live feed
·
PRReleasevia Quantisnow
Journey Medical Corporation logo
Fortress Biotech Inc. logo

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

ByQuantisnow·Wall Street's wire, on your screen.
DERM· Journey Medical CorporationFBIO· Fortress Biotech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DERM (Journey Medical Corporation), FBIO (Fortress Biotech Inc.) and more on Quantisnow.